Bristol-Myers Squibb Company
NYSE: BMY
Stock price
59.75 USD
(+2.38%) 5 years
Financial Performance
5Y price score: 3
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 58.3%
%
ㅤ
By default your notes are visible only to you.
42.5
52-week range
68.6
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
9.4 %
Dividend Yield TTM
4.2 %
Market cap $
$ 122,052
Price / Earnings TTM
13.2
Price / Book TTM
5.5
PEG TTM
0.1
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
43.4 %
20.9 %
58.3 %
Free cash flow per share growth
(13.6) %
6.9 %
722.3 %
Earnings per share growth
153.1 %
186.7 %
255.7 %
Founded: 1,989
Employees: 34,100
Business Summary:
Q&A
Contribute
By providing well-researched and detailed answer you increase your chance of becoming Top Contributor. TopFunds is free for all top contributors. Learn more
Latest Earnings Call Takeaways
2026 Q2 (Jul 30, 2026)
1) Strategy & Leadership
- Bristol-Myers Squibb (BMY) reported a strong Q2 2026, with a focus on transitioning its portfolio for long-term growth.
- The company is advancing a broad and differentiated pipeline, maintaining financial flexibility to invest in high-value opportunities.
- Leadership emphasized disciplined execution and confidence in the company’s ability to grow as it approaches the end of the decade.
2) Financial & Segment Results
- Total revenue for Q2 2026 increased by 5% YoY to approximately $13 billion.
- Growth portfolio revenue rose 14% to $7.6 billion, now representing nearly 60% of total revenue.
- Key products contributing to growth included:
- Eliquis: Up 21% to approximately $4.5 billion.
- Reblozyl: Grew 29%.
- Breyanzi: Increased 41%.
- Camzyos: Up 59% to $416 million.
- The company raised its full-year guidance for revenue and adjusted EPS based on strong first-half results.
3) Operational & Product Plans
- The pipeline includes pivotal readouts expected by the end of 2026, including:
- Admilparant for pulmonary fibrosis, with potential to redefine standard care.
- Iberdomide and Mezigdomide with upcoming PDUFA dates.
- Cobenfy in Alzheimer's psychosis, with data readouts anticipated in early 2027.
- The company is leveraging AI to enhance research and operational efficiency, partnering with Anthropic and NVIDIA.
4) Problems / Headwinds
- Delays in the ADEPT studies for Cobenfy and milvexian due to slower-than-expected event recruitment.
- The company is addressing study conduct deficiencies to mitigate risks in ongoing trials.
- The competition in the IPF market is intensifying with the launch of JASCAYD, raising the bar for new entrants like admilparant.
5) Guidance & Outlook / Investor Angle
- BMY expects continued strong performance in the second half of 2026, with Eliquis revenue growth projected at 20% to 25%.
- The legacy portfolio is expected to decline by 4% to 6% due to generic competition.
- The company maintains a strategic focus on business development, looking for opportunities to enhance its portfolio in therapeutic areas where it has expertise.
Bottom line: Bristol-Myers Squibb is positioned for sustained growth with a robust pipeline and strong financial performance, despite facing some operational challenges. The company's strategic focus on innovation and disciplined execution supports a positive outlook for shareholders.
Annual Reports, Presentations And IR Contacts
Go to the websiteBristol-Myers Squibb Company — Financial Overview, Stock Price, Market Cap
Bristol-Myers Squibb Company is a company. Founded in 1989. As of October 19, 2026, the company's market capitalization is $122051922500 with a current stock price of $59.75.